Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 61 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

6 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

13(59.1%)

Phase 3

5(22.7%)

N/A

3(13.6%)

Phase 4

1(4.5%)

22Total

Phase 2(13)

Phase 3(5)

N/A(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (61)

Showing 20 of 61 trials

NCT06557954Not Yet Recruiting

Cervical Cytology DNA Methylation for Cervical Cancer Screening

Role: lead

NCT06558019Not Yet Recruiting

Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence

Role: lead

NCT06491888Not ApplicableNot Yet Recruiting

A Multicenter Randomized Controlled Study of Photoelectric Detection in Cervical Cancer Screening

Role: lead

NCT06490380Completed

HRD Status Reference Standard Based on WGS

Role: lead

NCT06481930Not Yet Recruiting

A Multicenter Real-world Study of Screening of Cervical Cancer Based on Photoelectric Detection

Role: lead

NCT05801276Recruiting

ctDNA Methylation for Detecting Ovarian Cancer

Role: lead

NCT05801263Recruiting

ctDNA Methylation for Epithelial Ovarian Cancer

Role: lead

NCT05311579Phase 2Unknown

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Role: lead

NCT05311566Phase 2Recruiting

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Role: lead

NCT05310383Phase 2Unknown

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Role: lead

NCT05310305Unknown

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Role: lead

NCT05310318Unknown

Prognosis of Low-grade Endometrial Stromal Sarcoma

Role: lead

NCT05310344Phase 2Unknown

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

Role: lead

NCT05310331Phase 2Unknown

Donafenib for Recurrent Cervical Cancer

Role: lead

NCT05310370Unknown

HRD and Resistance to PAPPi in EOC Patients

Role: lead

NCT05310357Unknown

Chromosomal Instability in Ovarian Cancer

Role: lead

NCT05309122Unknown

Cervical Cancer Screening Strategies

Role: lead

NCT04651920Completed

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Role: lead

NCT05290415Unknown

Host DNA Methylation for Endometrial Cancer Screening

Role: lead

NCT05290922Unknown

DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening

Role: lead